# A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)

> **NCT03040401** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Vastra Gotaland Region** · enrollment: 15 (estimated)

## Conditions studied

- Leukemia, Myelomonocytic, Chronic

## Interventions

- **DRUG:** Cohort 1, Ceplene® and Proleukin®
- **DRUG:** Cohort 2, Ceplene® and Proleukin®
- **DRUG:** Cohort 3, Ceplene® and Proleukin®

## Key facts

- **NCT ID:** NCT03040401
- **Lead sponsor:** Vastra Gotaland Region
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-15
- **Primary completion:** 2018-12-15
- **Final completion:** 2019-12-15
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2017-12-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03040401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03040401, "A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03040401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*